{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Time to response was defined as the time from the first dose of M3258 to the documentation of first response (Complete Response \\[CR\\] or Partial Response \\[PR\\]). CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow. PR: \\>= 50% reduction of serum M-Protein and reduction in urinary M-protein by \\>= 90% or to \\< 200 mg/24 hours. In addition to the above, if present at baseline a \\>= 50% reduction in the size of soft tissue plasmacytomas is also required.","groups":[{"description":"Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) until disease progression.","id":"OG000","title":"M3258 10 mg QD"},{"description":"Participants received M3258 at a dose of 10 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG001","title":"M3258 10 mg Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG002","title":"M3258 20 mg Twice Per Week"}],"populationDescription":"Data could not be calculated as none of the participants showed response.","reportingStatus":"POSTED","timeFrame":"Time from the first dose of study treatment up to documentation of first response, assessed up to 18.2 months","title":"Time to Response as Assessed by Investigator Using International Myeloma Working Group (IMWG) Criteria","type":"SECONDARY"}